With over 15 years of experience in pharmaceutical and biotech management, Mr. Sunao Fujioka has been deeply involved in various oncology fields. He played a pivotal role as the lead for biomarkers/companion diagnostics during the Japanese launch of the immune checkpoint inhibitor. Before joining Alpha Fusion, he led the startup (bitBiome Inc.) launch and commercialization of the innovative genome analysis technology developed at a Japanese university. Since joining Alpha Fusion, he has served as CEO, driving the company's management to unlock the full potential of 211At drug discovery as quickly as possible. Sunao earned a M.S. degree from the Graduate School of Pharmaceutical Sciences at the University of Tokyo.

Dr. Yuichi Tomura is a drug hunter with over 30 years of leadership in pharmaceutical R&D, contributing to drug discovery, translational science, strategic planning, and organizational innovation. He earned his Ph.D. in Pharmacology from the Graduate School of Pharmaceutical Sciences, Tohoku University. He has extensive experience at Astellas Pharma Inc., where he advanced numerous drug candidates from discovery to clinical development, and at Alpha Fusion Inc., where he built a R&D team from the ground up and drives multiple pipeline programs. He also contributes to Japan's drug discovery ecosystem as Special Appointed Professor at Tohoku University, Board Auditor of the Japanese Pharmacological Society, and Program Officer at AMED.

Mr. Nobuo Ishida has been pursuing clinical development for various drugs, mainly in oncology/hematology, for over 35 years in foreign-based or domestic pharmaceutical companies. During his career, he took a lead in global clinical development for oncology drugs as a global project leader in the US for about four years. Nobuo joined Alpha Fusion in 2024. He has provided leadership in Clinical Development and played a key role in creating a clinical development plan/strategy for the company pipeline. Pharmacist

After completing graduate school, Mr. Hiroaki Kitajima gained experience in protocol development, monitoring, and clinical trial management for new drug development at a pharmaceutical company. Subsequently, he worked as a Project Manager, Clinical Operations Lead, and Line Manager at a CRO, where he was involved in driving various clinical trials, overseeing CRA training and organizational management, and managing team development. Currently engaged at a biotech with responsibilities that include planning and overseeing clinical trials, managing CROs and related vendors, and developing SOPs required for clinical development, demonstrating extensive expertise as a clinical development professional. M.S. in Biochemistry.

Mr. Yoshiharu Torikai has over 30 years of experience in regulatory affairs at pharmaceutical companies and CROs. As a regulatory expert, responsible for regulatory strategies and activities throughout the drug development, regulatory submission/approval, and post-marketing phases of new drugs, biologics, and regenerative products, with a primary focus on the oncology field. More than 15 years of experience as a General Marketing Compliance Officer, engaged in the establishment and management of the Marketing Authorization Holder License. M.S. in Pharmaceutical Sciences, Licensed Pharmacist.

Dr. Hideki Matsui currently leads drug discovery research for TAT using ^211^At, collaborating with the University of Osaka. Before joining Alpha Fusion, he worked as a preclinical pharmacologist and project leader in the fields of immunology and neuroscience at a pharmaceutical company, where he was involved in drug discovery research, spanning target discovery, compound selection, mechanism of action analysis, pharmacology, and compound optimization. His strengths include over 30 years of experience in drug discovery and a high level of expertise in identifying hit compounds for a wide range of target molecules. Hideki holds a PhD in Biological Sciences from the Graduate School of Life and Environmental Sciences at the University of Tsukuba.

A nuclear medicine expert driving next-generation targeted alpha therapy (TAT) drug discovery, with a strong foundation in both academia and the pharmaceutical industry. Dr. Sadaaki Kimura began his career at the National Cancer Center Hospital East, Department of Functional Imaging Development, where he focused on PET and SPECT research, particularly in hypoxia imaging. At Astellas Pharma, he advanced pharmacokinetic analysis of novel modalities using nuclear medicine and molecular imaging, while also leading disease modeling studies in animals. He actively fostered collaborations with academia and contributed to industry--academia--government initiatives, including activities with FIRM. Since joining Alpha Fusion, he has led the design of ^211^At--based drug discovery strategies, managed collaborative research and alliances, and shaped the company's intellectual property strategy. Sadaaki earned his Ph.D. in Pharmaceutical Sciences from Gifu Pharmaceutical University and is a licensed pharmacist.

A serial entrepreneur with over 20 years of experience in founding and growing biotech and CDMO ventures. Before entering the field of radiopharmaceuticals, Mr. Yusuke Kohno played key leadership roles---including CEO, CFO, and COO---as a founding member of biotech companies focused on peptide therapeutics and protein degraders. Before joining Alpha Fusion, he co-founded ARCALIS Inc., a CDMO specializing in mRNA medicines, where he contributed to building an integrated business model spanning CMC development through API and drug product manufacturing. At Alpha Fusion, he leads CMC development for ^211^At therapeutics and oversees the establishment of a robust radiopharmaceutical supply chain. Yusuke earned a M.S. degree from the Graduate School of Agriculture, Tokyo University of Agriculture and Technology.

Mr. Yoshihiro Kamio has been engaged in new drug development at a pharmaceutical company for over 30 years. As an expert in formulation research and industrialization (GMP), the advanced formulation design. Subsequently, he led drug development by driving regulatory strategy, planning clinical trials (GCP), and managing overall development projects. After transferring to a CMO, successfully led FDA inspections as a manufacturing supervisor. Actively and continuously participates in GMP-related academic conferences to stay consistently updated with the latest regulatory and technological developments. Yoshihiro earned a B.S. in Pharmacy from the School of Pharmacy, Tokyo University of Pharmacy and Life Sciences. Licensed Pharmacist.

Responsible for overall business operations, including strategy, fundraising, and corporate management. Before joining Alpha Fusion, Mr. Shoki Yamada engaged in private equity investments and new business development for major corporations at IGPI. Shoki holds an M.S. from the Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo.